Applied Genetic Technologies Corp (NASDAQ:AGTC) stock price target upped to $9.25, released a report earlier today by Zacks Investment Research
- Updated: October 17, 2016
Showing a price of $8.33, Applied Genetic Technologies Corp (NASDAQ:AGTC) traded -0.36% lower on the day. The last stock close price is down -41.27% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $10.24 and a 200-day average of $14.13. Trade Volume was up over the average, with 221,928 shares of AGTC changing hands over the typical 195,131
Reporting a potential upside of 0.11%, Zacks Investment Research bumped up the target of Applied Genetic Technologies Corp (NASDAQ:AGTC) to $9.25
See Chart Below
Applied Genetic Technologies Corp has a with a one year low of $8.15 and a one year high of $21.43 AGTC’s total market value is presently $0.
A total of 5 firms have reported on the stock. 0 brokers rating the stock a strong buy, 0 brokers rating the company a buy, zero analysts rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a one year target of $31.20.
Brief Synopsis About Applied Genetic Technologies Corp (NASDAQ:AGTC)
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.